1108199-50-3Relevant academic research and scientific papers
Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: From systemic to liver-targeting inhibitors
Ramtohul, Yeeman K.,Powell, David,Leclerc, Jean-Philippe,Leger, Serge,Oballa, Renata,Black, Cameron,Isabel, Elise,Li, Chun Sing,Crane, Sheldon,Robichaud, Joel,Guay, Jocelyne,Guiral, Sébastien,Zhang, Lei,Huang, Zheng
, p. 5692 - 5696 (2011)
Optimization of a lead thiazole amide MF-152 led to the identification of potent bicyclic heteroaryl SCD1 inhibitors with good mouse pharmacokinetic profiles. In a view to target the liver for efficacy and to avoid SCD1 inhibition in the skin and eyes where adverse effects were previously observed in rodents, representative systemically-distributed SCD1 inhibitors were converted into liver-targeting SCD1 inhibitors.
BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
-
Page/Page column 42, (2009/03/07)
Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis
